임상 레이더 AI | ||
|---|---|---|
임상시험 NCT07490860은(는) 폐암에 대해 대상자모집전 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial 57
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07490860은(는) 폐암에 대해 알아보는 중재연구입니다. 현재 상태는 대상자모집전이며, 2026년 7월 1일부터 참여 신청이 가능합니다. 57명의 참여자를 모집할 예정입니다. Fred Hutchinson Cancer Center이(가) 진행하는 이 연구는 2026년 12월 31일까지 진행될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 24일에 갱신되었습니다.
간단한 개요
This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (wi...더 보기
상세한 설명
OUTLINE: Participants are assigned to 1 of 2 aims.
AIM 1: Participants attend community advisory board (CAB) meetings over 60 minutes on study in support of the co-development and adaptation of the restorative justice-based LCS decision-making support intervention.
AIM 2: Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.
After completion of stud...
더 보기공식 제목
Integrating Restorative Practices to Enhance Shared Decision-Making and Uptake of Lung Cancer Screening in Black Community Members (RESTORE)
질환명
폐암기타 연구 식별자
NCT 번호
실제 연구 시작일
2026-07-01
최신 업데이트 게시
2026-03-24
예상 연구 완료일
2026-12-31
계획된 등록 인원
57
연구종류
중재연구
단계/상
해당 없음
상태
대상자모집전
주요 목적
스크리닝 (선별)
설계 할당
비랜덤화 배정
중재 모델
단일군설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
비개입Aim 1: Community advisory board (CAB) meetings Participants attend CAB meetings over 60 minutes on study in support of the co-development and adaptation of the restorative justice-based LCS decision-making support intervention. | 해당 없음 |
실험적Aim 2: Lung cancer screening (LCS) decision-making support session (intervention) Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study. | 교육적 개입 Attend LCS decision-making support session 설문 조사 관리 Ancillary studies 인터뷰 Ancillary studies 전자 건강 기록 검토 Ancillary studies |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Intervention acceptability | Assessed using the Acceptability of Intervention Measure (AIM). The AIM will be summarized and presented as a range of scores from 1 (low acceptability/appropriateness) to 5 (high acceptability/appropriateness). | At post-intervention (Day 1) |
Lung cancer screening knowledge | Will be assessed using the Lung Cancer Screening Knowledge 7 question score. Pre- and post-intervention responses will be compared via Chochran-Mantel-Haenszel and Friedman tests. | At pre- and post-intervention (both on Day 1) |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Readiness to screen | Will be assessed using the Lung Cancer Screening Health Belief Scales. Participant responses will be summarized with the median and range of scores at pre- and post-intervention. | At pre- and post-intervention (both on Day 1) |
Medical mistrust | Will be assessed using the Discrimination in Medical Setting and Group-Based Medical Mistrust scale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention. | At pre- and post-intervention (both on Day 1) |
Perceived smoking-related stigma | Will be assessed using the Cataldo Lung Cancer Stigma Scale: smoking-related subscale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention. | At pre- and post-intervention (both on Day 1) |
Shared decision-making (SDM) process | Will be assessed using the Shared Decision Making Questionnaire. Participant responses will be summarized with the median and range of scores, with 0 indicating no SDM behavior and 100 indicating ideal SDM behavior. | At post-intervention (Day 1) |
Completion of chest computed tomography (CT) | Will assess completion of chest CT within 90 days post-intervention with no comparison. | Up to 90 days post-intervention |
Intervention acceptability and refinement | Will recruit a subset of participants to participate in a semi-structured interview post-intervention to gain an in-depth understanding of intervention acceptability and intervention refinement, including participant perspectives about the integration of restorative justice-based lung cancer screening decision-making support. Qualitative interview data will be analyzed using a mixed inductive-deductive approach to thematic analysis. | At 90 days post-intervention |
참여 도우미
적격성 기준
연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
건강한 참가자 허용
네
- AIM 1: At least 18 years of age
- AIM 1: Individuals who represent LCS-eligible patients, serve as members of Black/African American (AA)-serving community-based organizations (CBOs), and represent key providers, public health, nursing, and medical staff stakeholders
- AIM 2: Identify as Black or African American
- AIM 2: Between ages 50-77
- AIM 2: Self-reported 20-pack year smoking history
- AIM 2: Ongoing commercial tobacco use within the past 15 years
- AIM 2: Proficiency in the English language
- AIM 1: Under 18 years of age
- AIM 1: Non-English speaking community advisory board (CAB) members
- AIM 1: Inability to read written English
- AIM 2: Has a documented chest CT within the past one year
- AIM 2: Personal history of lung cancer or symptoms associated with lung cancer
Fred Hutchinson Cancer Center- 아스트라제네카
- Go2 Foundation
연구 대표 연락처
연락처: Matthew Triplette, MD, MPH, 206-667-6335, [email protected]
1 1개국에 임상시험 장소
Washington
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States
Matthew Triplette, MD, MPH, 연락처, 206-667-6335, [email protected]
Matthew Triplette, MD, MPH, 책임연구자